![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Phase 1b Efficacy and Safety of NVR 3-778, a First-In-Class HBV Core Inhibitor, in HBeAg-Positive Patients with Chronic HBV Infection
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
M-F Yuen1, DJ Kim2, F Weilert3, H L-Y Chan4, J Lalezari5, SG Hwang6, T Nguyen7, S Liaw8, N Brown8, K Klumpp8, L Flores8, G Hartman8, EJ Gane9
1Queen Mary Hospital, Univ. of Hong Kong, Hong Kong; 2Hallym University, ChuncheonSacred Heart Hospital, Gangwon-do, Republic of Korea; 3Waikato Hospital, Hamilton, New Zealand; 4Prince of Wales Hospital, Chinese Univ. of Hong Kong, Hong Kong; 5Quest Clinical Research, San Francisco, CA, USA; 6CHA BundangMedical Center, Gyeonggi-do, Republic of Korea; 7Research and Education, Inc., San Diego, CA, USA; 8Novira Therapeutics, Doylestown, PA, USA; 9Auckland Clinical Studies, Auckland, New Zealand
![AASLD1.gif](../images/120215/120215-2/AASLD1.gif)
![AASLD2.gif](../images/120215/120215-2/AASLD2.gif)
![AASLD3.gif](../images/120215/120215-2/AASLD3.gif)
![AASLD4.gif](../images/120215/120215-2/AASLD4.gif)
![AASLD5.gif](../images/120215/120215-2/AASLD5.gif)
![AASLD6.gif](../images/120215/120215-2/AASLD6.gif)
![AASLD7.gif](../images/120215/120215-2/AASLD7.gif)
![AASLD8.gif](../images/120215/120215-2/AASLD8.gif)
![AASLD9.gif](../images/120215/120215-2/AASLD9.gif)
![AASLD10.gif](../images/120215/120215-2/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|